tradingkey.logo

BRIEF-Candid Therapeutics Enters Into Agreement With Wuxi Biologics On Trispecific T-Cell Engager

ReutersJan 7, 2025 12:02 AM

-

  • CANDID THERAPEUTICS ENTERS INTO AGREEMENT WITH WUXI BIOLOGICS ON TRISPECIFIC T-CELL ENGAGER

  • CANDID THERAPEUTICS - WUXI BIOLOGICS TO RECEIVE UP TO $925 MILLION IN PAYMENTS AND MILESTONES

  • CANDID - PLANS TO COMPLETE IND ENABLING STUDIES TO ENABLE FIRST-IN-HUMAN STUDIES IN FIRST HALF OF 2026

Source text: ID:nBw7pY2dZa

Further company coverage: 2269.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI